Asparaginase erwinia chrysanthemi - Biologic Drug Details

Summary for asparaginase erwinia chrysanthemi

Tradenames:	1
High Confidence Patents:	2
Applicants:	2
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for asparaginase erwinia chrysanthemi

Recent Clinical Trials for asparaginase erwinia chrysanthemi

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Jazz Pharmaceuticals	PHASE2
University of Washington	PHASE2
National Cancer Institute (NCI)	PHASE1

See all asparaginase erwinia chrysanthemi clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for asparaginase erwinia chrysanthemi Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for asparaginase erwinia chrysanthemi Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Jazz Pharmaceuticals, Inc.	ERWINAZE	asparaginase erwinia chrysanthemi	For Injection	125359	4,729,957	2006-10-08	DrugPatentWatch analysis and company disclosures
Jazz Pharmaceuticals Ireland Limited	RYLAZE	asparaginase erwinia chrysanthemi (recombinant)-rywn	Injection	761179	10,787,671	2038-10-17	DrugPatentWatch analysis and company disclosures
Jazz Pharmaceuticals Ireland Limited	RYLAZE	asparaginase erwinia chrysanthemi (recombinant)-rywn	Injection	761179	8,288,127	2029-07-30	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for asparaginase erwinia chrysanthemi Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Jazz Pharmaceuticals, Inc.	ERWINAZE	asparaginase erwinia chrysanthemi	For Injection	125359	10,287,294	2036-07-08	Patent claims search
Jazz Pharmaceuticals, Inc.	ERWINAZE	asparaginase erwinia chrysanthemi	For Injection	125359	10,787,671	2038-10-17	Patent claims search
Jazz Pharmaceuticals, Inc.	ERWINAZE	asparaginase erwinia chrysanthemi	For Injection	125359	10,821,160	2037-03-01	Patent claims search
Jazz Pharmaceuticals, Inc.	ERWINAZE	asparaginase erwinia chrysanthemi	For Injection	125359	10,933,061	2038-12-21	Patent claims search
Jazz Pharmaceuticals, Inc.	ERWINAZE	asparaginase erwinia chrysanthemi	For Injection	125359	9,920,311	2035-08-05	Patent claims search

Last updated: April 25, 2026

Asparaginase Erwinia chrysanthemi: Market Dynamics and Financial Trajectory

Asparaginase erwinia chrysanthemi (recombinant), marketed in multiple regions under brand names such as Erwinase and Rylaze (formulation/authorization varies by geography), participates in the oncology biologics market defined by (1) acute lymphoblastic leukemia (ALL) treatment demand, (2) competitive substitution across asparaginase products, and (3) supply- and manufacturing-constrained pricing power. Financial trajectory is shaped by the balance of net price per treated patient versus share shifts among pegylated vs non-pegylated asparaginase options and by payer coverage decisions driven by adverse-event profiles and administration logistics.

Where does asparaginase erwinia fit in the asparaginase competitive set?

The clinical role of asparaginase erwinia chrysanthemi is primarily ALL and hypersensitivity management within asparaginase regimens. Its market dynamics are anchored to three real-world substitution drivers:

1. Indication adjacency to pegylated E. coli asparaginase and other asparaginase enzymes

   • Patients who become ineligible for E. coli-derived asparaginase due to hypersensitivity move into alternative asparaginase options, where Erwinia-based products are the standard substitute in many treatment pathways.

2. Administration and logistics

   • Formulations and dosing schedules influence total treatment burden for hospitals. In oncology procurement, scheduling fit affects pull-through.

3. Safety and tolerance profiles

   • Hypersensitivity and other adverse events determine switching rates within multi-agent chemotherapy cycles, directly affecting demand.

Competitive framing by product archetype

• Pegylated asparaginase (E. coli-derived): long half-life, established backbone where tolerated.
• Non-pegylated options and alternatives: used when pegylated product is interrupted or not feasible.
• Erwinia-derived asparaginase: used when hypersensitivity or other intolerance limits the E. coli products.

For regulatory and clinical anchoring, the FDA labeling for Rylaze (asparaginase erwinia chrysanthemi-rywn) supports use in ALL and defines safety warnings relevant to procurement and uptake. FDA prescribing information specifies boxed warnings for severe hypersensitivity and other serious risks, and outlines administration constraints that shape hospital workflow and payer policies. [1]

---

What market drivers push volume and pricing?

Demand is driven by treated ALL cohorts and by switching rates within asparaginase blocks of induction and consolidation. Pricing is shaped by hospital tendering, payers’ preference for the lowest total cost per completed regimen, and by manufacturing availability.

1) Patient pool and regimen persistence

ALL incidence and treatment intensity determine the ceiling for asparaginase consumption. Within those patients, the asparaginase portion is dosing-dense, so even modest penetration changes can move revenue materially. The erwinia product’s penetration rises when:

• E. coli pegylated asparaginase hypersensitivity occurs
• Patients require alternative asparaginase mid-regimen
• Protocols in specific geographies favor erwinia-based sequencing

The FDA label for Rylaze includes safety monitoring and administration guidance that hospitals translate into practical treatment completion targets. Those completion targets drive purchasing decisions because interruption has clinical and operational consequences. [1]

2) Supply constraints and manufacturing risk premiums

Asparaginase manufacturing is complex and has a history of market volatility across the class. When supply tightens, biologics providers often gain short-term pricing power because hospitals must maintain continuity of chemotherapy. That pricing power is typically temporary but can affect annual revenue trajectories even without long-term share gains.

3) Payer coverage and tender economics

In many markets, procurement levers include:

• reimbursement rates and prior authorization
• substitution rules by treatment guideline adherence
• pharmacy and infusion center cost accounting

Because asparaginase is administered in oncology infusion settings, total regimen cost (drug plus administration logistics plus management of adverse events) tends to dominate payer negotiations, which favors products with fewer protocol-disrupting events and predictable administration.

---

How does product competition affect share and trajectory?

The competitive set influences whether asparaginase erwinia is positioned as:

• a default backbone option (lower share dependence on switching), or
• a replacement option (higher share dependence on hypersensitivity incidence and protocol behavior)

In most real-world pathways, erwinia products act as insurance against treatment-limiting hypersensitivity, giving them revenue stability during periods where E. coli pegylated products face tolerance issues. The net effect on financial trajectory depends on two opposing forces:

Force A: Switching-driven demand

• A broader switching base increases volume even if baseline asparaginase use is flat.

Force B: Competitive displacement

• If competing asparaginase options are preferred in guidelines, or if improved tolerance broadens continued use of the incumbent, erwinia substitution can slow.

Rylaze labeling and clinical positioning support its role in the asparaginase regimen where substitution is needed, shaping its share capture logic. [1]

---

What financial trajectory patterns are typical for asparaginase erwinia?

Without a single universally consistent global reporting line for every branded version, the trajectory should be evaluated along three quantifiable dimensions: unit demand (patients treated), net selling price, and duration of supply/coverage cycles. The drug class often shows:

1. Short-cycle revenue variability

   • Supply disruptions and tender cycles affect quarterly revenue more than long-duration product lifecycle trends.

2. Mid-cycle share changes

   • Hospital formulary updates and protocol changes influence switching rates and thus demand during chemotherapy seasons.

3. Lifecycle compression around market expansions

   • Additional approvals, revised indication wording, or formulary access can trigger revenue step-ups.

Rylaze’s FDA approval history and the label’s safety framework affect payer comfort and procurement stability. FDA documentation establishes dosing and safety requirements that hospitals incorporate into treatment pathways. [1]

---

What do market participants expect for near-to-mid term?

Near-term outlook is typically anchored on:

• sustained ALL treatment demand
• ongoing need for alternative asparaginase after hypersensitivity
• competition among asparaginase enzymes
• manufacturing continuity

From a market dynamics perspective, the dominant factor for financial trajectory is whether hospitals maintain consistent asparaginase completion rates. The Rylaze label’s warnings and administration instructions materially affect that continuity. [1]

---

Financial and Commercial Model: What moves revenue most?

Key revenue drivers to monitor

A practical revenue bridge for asparaginase erwinia uses four inputs:

Driver	What to watch	Financial direction
Treated ALL cohort	new diagnoses, regimen adoption	Up/down volume baseline
Switching rate within regimen	hypersensitivity rates to alternate products; protocol preference	Up/down volume tied to clinical need
Net price and tender terms	hospital procurement cadence; supply tightness	Up/down per-patient revenue
Supply reliability	manufacturing yield, distribution continuity	Up/down realized sales

This framework matches how procurement behaves in high-acuity infusion drugs: demand is sticky, but realized sales depend on whether supply and contract terms align with infusion schedules.

---

Regulatory and safety positioning that shapes commercialization

How do FDA warnings influence procurement and payer behavior?

Rylaze’s labeling includes major safety considerations, including a boxed warning for severe hypersensitivity and other serious risks. These label elements matter commercially because they drive:

• pre-treatment screening and monitoring protocols
• contraindication filtering
• management costs for adverse events
• hospital confidence in predictable administration

Rylaze’s prescribing information details these safety risks and administration constraints relevant to clinical operations. [1]

---

Competitive and strategic implications for investors and R&D planners

What does this mean for unit economics and risk?

• Revenue stability is tied to switching need, not only baseline ALL incidence.
• Margin outcomes depend on net price vs supply cost in years with manufacturing volatility.
• Competitive risk concentrates on protocol shifts that reduce switching to Erwinia or increase use of alternative asparaginase enzymes.

The commercial strategy therefore focuses on maintaining consistent access in infusion networks and preserving formulary placement where hypersensitivity-based substitution is expected.

---

Key Takeaways

• Asparaginase erwinia chrysanthemi’s market dynamics are defined by ALL regimen demand and by substitution/switching when patients cannot continue other asparaginase options.
• Financial trajectory tends to reflect tender cycles, supply continuity, and switching-rate changes more than broad market expansion alone.
• FDA safety and administration requirements for Rylaze shape payer and hospital confidence, influencing procurement continuity and demand pull-through. [1]

---

FAQs

1) Is asparaginase erwinia primarily a first-line or replacement therapy in ALL?

It is used in ALL regimens, with commercial pull driven largely by replacement after intolerance or hypersensitivity to other asparaginase options, reflected in its established substitution role and prescribing guidance. [1]

2) What most directly drives quarterly revenue changes?

Supply availability and hospital tender timing interact with infusion schedules, producing quarter-to-quarter variability even if underlying ALL patient demand changes slowly.

3) How does safety labeling affect commercial adoption?

Boxed and serious safety warnings drive hospital monitoring protocols and operational readiness, which can influence formulary placement and payer authorization decisions. [1]

4) What competitive threats are most material?

Protocol shifts and formulary preferences across the asparaginase class that reduce reliance on erwinia-based substitution, or that favor other asparaginase enzymes for hypersensitivity scenarios.

5) What is the most useful way to model financial trajectory?

A revenue bridge using treated patient volume, switching rate, net price from tenders, and realized supply reliability produces the most decision-relevant view for this infusion biologic.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Rylaze (asparaginase erwinia chrysanthemi-rywn) prescribing information. FDA label documentation.